Cefepime neurotoxicity | Rest of cohort | P value | |
---|---|---|---|
n = 15 | n = 85 | ||
Age, years, mean | 69 | 66 | 0.16 |
Male gender, n (%) | 11 (73) | 50 (59) | 0.39 |
Acute kidney injury, n (%) | 13 (87) | 64 (75) | 0.51 |
Chronic kidney disease, n (%) | 10 (67) | 30 (35) | 0.042 |
Hemodialysis, n (%) | 4 (27) | 28 (33) | 0.77 |
Peak creatinine, median (IQR) | 2.8 (1.7-3.1)* | 2.3 (1.5-3) | 0.36 |
Nadir eGFR, median (IQR) | 22.5 (20.8-34.3) | 27.5 (18-45) | 0.53 |
Mean daily cefepime dose, g, median (IQR) | 2.5 (1.7-4)* | 2.5 (2-3.5) | 0.66 |
Cefepime duration, days, median (IQR) | 5 (4.8-7.3)* | 7 (4-10) | 0.26 |
Appropriate dose reduction for renal function, n (%) | 4 (29)* | 64 (75) | 0.001 |